SKILLCELL
1.10.2020 18:25:11 CEST | Business Wire | Press release
EasyCOV, a virological saliva detection test for COVID19, has shown a sensitivity of 88% and a specificity 99% during a clinical trial performed at the testing center operated by the teaching hospital of Montpellier. The test relies on an optimized thermal protocol that provides the results in 40 minutes.
EasyCOV, developed by SkillCell in collaboration with the CNRS (French National Center for Scientific Research), is a saliva test that can be run in the field and that provides results in the form of a change of color in no more than 40 minutes. Performed by a healthcare professional, the test requires the collection of 200 microliters of saliva, approximately 4 drops, from under the patient’s tongue. The sample is heated successively in two tubes using the nomadic heating device EasyVID (developed and produced by TRONICO, sister company of SkillCell). A test turning bright yellow indicates that the virus has been detected while an orange test is negative.
A double-blind clinical trial has been conducted at the teaching hospital of Montpellier, France, in real life conditions at the testing center operated by the hospital. During this clinical trial, nasopharyngeal and saliva samples were collected simultaneously and analyzed via RT PCR. These two analyses were used as a basis to establish the infection status of the participants. This status was then compared to the results of EasyCOV test. This analysis showed a sensitivity of 87.5% and a specificity of 99.4% for 220 participants, including 40 positive patients with and without symptoms. EasyCOV test was performed using a thermal protocol giving results in 40 min.
EasyCOV demonstrates with this trial that it is high quality, faster, cost-efficient and not invasive test that can be performed in a large variety of locations without requiring heavy investments.
Alexandra Prieux, President of SkillCell commented « EasyCOV is a unique and necessary tool in the fight against COVID 19. It is a real satisfaction for the team that our test is able to bring a concrete answer to the sanitary and economic challenges that we face today. ».
The EasyCov programme is supported by the French Ministry of Armed Forces via the Direction Générale de l’Armement (Directorate General of Armaments - DGA) and the Agence de l’Innovation de Défense (Defense Innovation Agency - AID).
About SKILLCELL
SkillCell develops in-field diagnostic tests using its simplicity-centered approach: tests capable of being used by anybody, anywhere and at any time. Founded in Guadeloupe in 2017, the company has offices in France in Jarry (Guadeloupe), Paris and Montpellier. The SkillCell team brings together scientific experts and seasoned manufacturers to find solutions to medical and environmental diagnostic testing issues by providing relevant, high-quality information that allows users to make well-informed choices with full transparency. SkillCell is a subsidiary of ALCEN group. For more information: www.skillcell-alcen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005914/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom